Isoform-specific roles of AMPK in synaptic failure and memory deficit in Alzheimer's Disease

NIH RePORTER · NIH · R01 · $526,340 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract The basic molecular mechanisms associated with Alzheimer’s disease (AD) remain a critical knowledge gap that prevents identification of effective therapeutic targets and diagnostic/prognostic biomarkers. The current proposal will address this gap by studying the role of signaling pathways associated with AMP-activated protein kinase (AMPK) isoforms in AD. AMPK functions as a central cellular energy sensor to maintain energy homeostasis. Moreover, AMPK is a nexus to incorporate multiple signaling pathways for de novo protein synthesis (mRNA translation). Importantly, both disruptions in energy homeostasis and impairments in de novo protein synthesis are implicated in cognitive syndromes associated with neurodegenerative diseases, including AD. The kinase catalytic subunit of AMPK exists in two isoforms in brain: α1 and α2, and their roles in synaptic plasticity and memory are unknown. We generated brain- and isoform-specific conditional AMPKα1 and α2 knockout mice (AMPKα1 cKO and AMPKα2 cKO), and performed behavioral, electrophysiology, imaging, and biochemical tests to characterize isoform-specific phenotypes. Driven by our preliminary data, our central hypothesis is that disruption of AMPK isoform homeostasis represents a key molecular mechanism underlying AD-associated impairments of synaptic plasticity and memory defects. Three specific aims are formulated to test the hypothesis. Aim 1 seeks to identify isoform-specific roles of AMPK in hippocampal synaptic plasticity and memory formation. Aim 2 is designed to determine AMPK isoform-specific regulation of synaptic failure and memory impairment in Tg19959 AD mouse model. Aim 3 is designed to elucidate AMPK isoform-specific effects on de novo protein synthesis and brain Aβ pathology in Tg19959 AD mouse model. The project proposes in-depth analyses using multiple state-of-art methods in neuroscience and AD, including mouse genetics, synaptic electrophysiology, confocal imaging, and behavioral tests. Moreover, novel methods to measure de novo protein synthesis combined with mass spectrometry/proteomics approach will be applied to reveal identities of proteins in AD brains whose synthesis is dysregulated because of abnormal signaling due to disruption of AMPK isoform homeostasis. This multidisciplinary approach will enable us to identify detailed cellular/molecular mechanisms associated with aberrant AMPK signaling in AD pathogenesis, providing insights into novel therapeutic targets and diagnostic biomarkers for AD and other dementia syndromes.

Key facts

NIH application ID
9925166
Project number
5R01AG055581-04
Recipient
WAKE FOREST UNIVERSITY HEALTH SCIENCES
Principal Investigator
Tao Ma
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$526,340
Award type
5
Project period
2017-07-15 → 2022-04-30